Overdiagnosis and false positives present significant clinical problems in the prevention, detection and treatment of cancer. Therefore, there is an unmet clinical need to more accurately identify early-stage aggressive cancers and distinguish lesions that are life threatening from those that are not. The Consortium for Imaging and Biomarkers (CIB) seeks to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk, and cancer diagnosis by integrating imaging strategies with biomarkers into complementary approaches.
Read more About CIB.
Members of CIB
- Beckman Research Institute
- Boston University
- Fred Hutchinson Cancer Center
- Houston Methodist Research Institute
- Rice University
- Rush University Medical Center
- University of California, San Francisco
- University of Miami
- University of Michigan
- University of North Carolina
- University of Texas MD Anderson
- University of Washington
- University of Wisconsin-Madison
- Vanderbilt University
News and Events
Date: June 29, 2020
Location: via WebEx
The annual meeting is a closed meeting.
CIB webinars occur every 4th Monday of the month at 1:00p.m. ET — For WebEx information please contact CIB support.
PAR-22-131 Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)
Expiration Date: 09/08/2025